Drug Profile
Ponatinib companion diagnostic - Takeda/MolecularMD
Latest Information Update: 07 Sep 2021
Price :
$50
*
At a glance
- Originator ARIAD Pharmaceuticals
- Developer MolecularMD
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
- 25 Sep 2013 Discontinued - Preregistration for Acute lymphoblastic leukaemia in USA (unspecified route)
- 25 Sep 2013 Discontinued - Preregistration for Chronic myeloid leukaemia in USA (unspecified route)